Boothbay Fund Management’s Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 CLDI.WS Stock Holding History

Boothbay Fund Management’s Portfolio CLDI.WS Stock Details CLDI.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-22,626	Closed	-$223K	–	2531
2022 Q3	$223K	Hold	22,626	–	–	0.01%	1748
2022 Q2	$225K	Hold	22,626	–	–	0.01%	1660
2022 Q1	$224K	Hold	22,626	–	–	0.01%	1822
2021 Q4	$222K	Buy	+22,626	New	+$12.8K	0.01%	1438

Other funds holding CLDI.WS

RCM

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

SCM

Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return

ICM

Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

EFI

EHP Funds Inc Toronto, Canada $43.6M AUM 69.08% 1-Year Est. Return

Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

Boothbay Fund Management's CLDI.WS Position: Q4 2022 in Review

Boothbay Fund Management sold out of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) in Q4 2022, closing a stake of 22,626 shares — an estimated $223K sold.

Boothbay Fund Management first reported a position in CLDI.WS in Q4 2021 and held it in 4 quarters. The position peaked at $225K in Q2 2022. 24 funds tracked by Wall St. Rank hold CLDI.WS as of Q4 2022.

Boothbay Fund Management reported no remaining Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position as of Q4 2022 after selling out during the quarter.
Boothbay Fund Management sold 22,626 Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 shares in Q4 2022, an estimated $223K.
Boothbay Fund Management first reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in Q4 2021 and held it in 4 quarters.
Boothbay Fund Management's Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position peaked at $225K in Q2 2022.
24 funds tracked by Wall St. Rank held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 as of Q4 2022.

Based on Boothbay Fund Management's 13F filing for Q4 2022, filed 14 Feb 2023.